All In Biotech

Drug Trial Radar · NCT06877650

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors.

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

436

Planned (sponsor's estimate)

Start

Apr 11, 2025

Primary completion

Mar 30, 2028

Study completion Mar 30, 2029

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Mar 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108 injection, and to determine the RP2D/schedule for subsequent studies.

Conditions

  • Advanced Malignant Tumors

Interventions

  • JMT108Drug

    Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.

  • PembrolizumabDrug

    Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.

  • IvonescimabDrug

    Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity(DLT)Time frame: Approximately 28 days.
  2. Adverse Events (AEs)Time frame: through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.